Relation of C-reactive Protein/ Albumin Ratio and Coagulation Profile in Acute Myeloid Leukemia Patients
NCT06714071 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2025-01-28
Summary
The investigators will investigate the relation between CAR and coagulation profile in newly diagnosed AMl patients
Conditions
Interventions
- DIAGNOSTIC_TEST
-
CRP and Albumin and coagulation profile
CRP and Albumin and coagulation profile
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
sohir kamel, prof · Director
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-04-30
- Primary Completion
- 2027-03-01
- Completion
- 2027-05-01
Countries
- Egypt
Study Locations
More Related Trials
-
Outcomes of Acute Myeloid Leukemia Patients
NCT04392310 ·Status: UNKNOWN
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression
NCT05512104 ·Status: UNKNOWN
-
CD155 Expression in Acute Myeloid Leukemia
NCT06369662 ·Status: COMPLETED
-
The Prognostic Significance of Platelet to White Blood Cell Ratio (PWR) in Patients With Acute Myeloid Leukemia
NCT07115537 ·Status: NOT_YET_RECRUITING
-
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT06652685 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
NCT01385150 ·Status: COMPLETED
-
ABO and Rh Blood Group Frequencies in Acute Leukemia Patients
NCT07108010 ·Status: NOT_YET_RECRUITING
-
Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)
NCT02662920 ·Status: COMPLETED
-
Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions
NCT07080970 ·Status: NOT_YET_RECRUITING
-
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
NCT07177079 ·Status: RECRUITING ·Phase: PHASE1
-
Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
NCT06535113 ·Status: RECRUITING
-
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
NCT00897182 ·Status: COMPLETED
-
Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers
NCT03337516 ·Status: UNKNOWN ·Phase: NA
-
Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
NCT07250217 ·Status: RECRUITING ·Phase: NA
-
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT01390337 ·Status: COMPLETED ·Phase: PHASE1
-
Endothelial Function, Arterial Stiffness and Components
NCT01439217 ·Status: COMPLETED
-
Daunorubicin + Cytarabine + Venetoclax in de Novo AML
NCT06697327 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
NCT00003931 ·Status: COMPLETED
-
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
NCT01484171 ·Status: UNKNOWN ·Phase: PHASE3
-
Leptin: A Marker for AML Chemo-Sensitivity
NCT07163728 ·Status: RECRUITING
-
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia
NCT02581917 ·Status: COMPLETED
-
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
NCT06451861 ·Status: RECRUITING ·Phase: PHASE2
-
An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT05577611 ·Status: UNKNOWN ·Phase: PHASE1
-
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
NCT06279572 ·Status: RECRUITING